SAN DIEGO, March 27, 2020 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage
biopharmaceutical company, announced today that Chief Executive
Officer Saundra Pelletier will
present an overview of the Company and business updates at the
upcoming Solebury Trout Virtual Investor Conference.
|
Date:
|
Thursday, April 2,
2020
|
|
Time:
|
11:00 am – 11:25 am
EDT
|
|
Access:
|
https://evofem.investorroom.com or click
here
|
The archived webcast of the event will be available 24 hours
following the presentation in the Investors section of the Evofem
Biosciences website at www.evofem.com.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a clinical-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health.
Evofem Biosciences aims to advance the lives of women by developing
innovative solutions, such as woman-controlled contraception and
potential protection from certain sexually transmitted infections
(STIs). The Company's lead product candidate, Phexxi™, is currently
being reviewed by the U.S. Food and Drug Administration for
prevention of pregnancy. The investigational candidate EVO100
is being evaluated for prevention of urogenital transmission of
both Chlamydia trachomatis infection (chlamydia)
and Neisseria gonorrhoeae infection (gonorrhea) in
women. For more information regarding Evofem, please
visit www.evofem.com.
Phexxi™ and Multipurpose Vaginal pH Regulator (MVP-R™) are
trademarks of Evofem Biosciences, Inc.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775
Media Contact
Cara
Miller
Evofem Biosciences, Inc.
cmiller@evofem.com
O: (858) 550-1900 x272
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-solebury-trout-virtual-investor-conference-301030755.html
SOURCE Evofem Biosciences, Inc.